202 related articles for article (PubMed ID: 19910702)
41. Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2).
Chiluiza D; Krishna S; Schumacher VA; Schlöndorff J
J Biol Chem; 2013 Jun; 288(25):18407-20. PubMed ID: 23645677
[TBL] [Abstract][Full Text] [Related]
42. Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.
Grond J; Koudstaal J; Elema JD
Kidney Int; 1985 Feb; 27(2):405-10. PubMed ID: 3990093
[TBL] [Abstract][Full Text] [Related]
43. Novel role of NOD2 in mediating Ca2+ signaling: evidence from NOD2-regulated podocyte TRPC6 channels in hyperhomocysteinemia.
Han H; Wang Y; Li X; Wang PA; Wei X; Liang W; Ding G; Yu X; Bao C; Zhang Y; Wang Z; Yi F
Hypertension; 2013 Sep; 62(3):506-11. PubMed ID: 23856489
[TBL] [Abstract][Full Text] [Related]
44. Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes.
Li Z; Xu J; Xu P; Liu S; Yang Z
Cell Prolif; 2013 Feb; 46(1):76-85. PubMed ID: 23294354
[TBL] [Abstract][Full Text] [Related]
45. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode.
Kawakami H; Kamiie J; Yasuno K; Kobayashi R; Aihara N; Shirota K
Nephrol Dial Transplant; 2012 Apr; 27(4):1324-30. PubMed ID: 21862459
[TBL] [Abstract][Full Text] [Related]
46. Angiotensin II has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli.
Ilatovskaya DV; Palygin O; Chubinskiy-Nadezhdin V; Negulyaev YA; Ma R; Birnbaumer L; Staruschenko A
Kidney Int; 2014 Sep; 86(3):506-14. PubMed ID: 24646854
[TBL] [Abstract][Full Text] [Related]
47. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Celik Y; Celik F
Transl Res; 2006 Jul; 148(1):46. PubMed ID: 16887498
[No Abstract] [Full Text] [Related]
48. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat.
Kim YH; Goyal M; Kurnit D; Wharram B; Wiggins J; Holzman L; Kershaw D; Wiggins R
Kidney Int; 2001 Sep; 60(3):957-68. PubMed ID: 11532090
[TBL] [Abstract][Full Text] [Related]
49. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury.
Eid AA; Ford BM; Bhandary B; de Cassia Cavaglieri R; Block K; Barnes JL; Gorin Y; Choudhury GG; Abboud HE
Diabetes; 2013 Aug; 62(8):2935-47. PubMed ID: 23557706
[TBL] [Abstract][Full Text] [Related]
50. Upregulation of nestin protects podocytes from apoptosis induced by puromycin aminonucleoside.
Wen D; You L; Zhang Q; Zhang L; Gu Y; Hao CM; Chen J
Am J Nephrol; 2011; 34(5):423-34. PubMed ID: 21952051
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases.
Eid AA; Gorin Y; Fagg BM; Maalouf R; Barnes JL; Block K; Abboud HE
Diabetes; 2009 May; 58(5):1201-11. PubMed ID: 19208908
[TBL] [Abstract][Full Text] [Related]
52. Effects of podocyte injury on glomerular development.
Ma J; Rossini M; Yang HC; Zuo Y; Fogo AB; Ichikawa I
Pediatr Res; 2007 Oct; 62(4):417-21. PubMed ID: 17667850
[TBL] [Abstract][Full Text] [Related]
53. Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury.
Liu S; Shi W; Xiao H; Liang X; Deng C; Ye Z; Mei P; Wang S; Liu X; Shan Z; Liang Y; Zhang B; Wang W; Liu Y; Xu L; Xia Y; Ma J; Li Z
PLoS One; 2012; 7(7):e41331. PubMed ID: 22848465
[TBL] [Abstract][Full Text] [Related]
54. TGF-β1 induces podocyte injury through Smad3-ERK-NF-κB pathway and Fyn-dependent TRPC6 phosphorylation.
Yu L; Lin Q; Liao H; Feng J; Dong X; Ye J
Cell Physiol Biochem; 2010; 26(6):869-78. PubMed ID: 21220918
[TBL] [Abstract][Full Text] [Related]
55. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia.
Abais JM; Zhang C; Xia M; Liu Q; Gehr TW; Boini KM; Li PL
Antioxid Redox Signal; 2013 May; 18(13):1537-48. PubMed ID: 23088210
[TBL] [Abstract][Full Text] [Related]
56. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Toyonaga J; Tsuruya K; Ikeda H; Noguchi H; Yotsueda H; Fujisaki K; Hirakawa M; Taniguchi M; Masutani K; Iida M
Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
[TBL] [Abstract][Full Text] [Related]
57. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis.
Takeuchi S; Hiromura K; Tomioka M; Takahashi S; Sakairi T; Maeshima A; Kaneko Y; Kuroiwa T; Nojima Y
Nephron Exp Nephrol; 2010; 116(1):e3-10. PubMed ID: 20502051
[TBL] [Abstract][Full Text] [Related]
58. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis.
Guo J; Ananthakrishnan R; Qu W; Lu Y; Reiniger N; Zeng S; Ma W; Rosario R; Yan SF; Ramasamy R; D'Agati V; Schmidt AM
J Am Soc Nephrol; 2008 May; 19(5):961-72. PubMed ID: 18256352
[TBL] [Abstract][Full Text] [Related]
59. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.
Ortmann J; Amann K; Brandes RP; Kretzler M; Münter K; Parekh N; Traupe T; Lange M; Lattmann T; Barton M
Hypertension; 2004 Dec; 44(6):974-81. PubMed ID: 15545511
[TBL] [Abstract][Full Text] [Related]
60. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol.
Ricardo SD; Bertram JF; Ryan GB
Exp Nephrol; 1995; 3(5):270-9. PubMed ID: 7583048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
